Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.

INTRODUCTION

Many therapeutic strategies have been adopted in the treatment of anterior uveitis, and it includes corticosteroids and NSAIDs. But, the successful delivery of these drugs is restricted due to limitations of conventional formulation. This review emphasizes on the possible benefits and strategies for development of various novel nanocarriers.

AREAS COVERED

The article explores the various polymers involved in the preparation of novel nanocarriers like polymeric nanoparticles, micelles, microemulsion, liposomes and cubosomes. Reported clinical experimental findings are screened and also discussed in this review.

EXPERT OPINION

The principle behind the development of different nanocarriers is to overcome the limitations imposed by conventional formulations. Several efforts have been made by the researchers in achieving these objectives, but the major challenge with nanosystems remains the requirement of excipients that have unknown or objectionable toxicity profile and are not approved by regulatory authorities. This review is an attempt to provide comprehensive information for the scientists working in the concerned research area.